On Monday, for the third straight day, shares of CRISPR Therapeutics (NASDAQ: CRSP) stock declined, falling 11.2% through 11:30 a.m. ET -- which is kind of crazy when you think about it.
Just three days ago, CRISPR announced that the U.S. Food and Drug Administration (FDA) approved its Casgevy treatment for sickle cell anemia. Yet instead of rising, shares of this innovative biotech stock have fallen more than 19% over the last three days.
Why?
Source Fool.com